Skip to main content
Year archive

Vivesto — 2020 filings

All 53 regulatory filings released by Vivesto (VIVE) in 2020, sourced directly from the official regulator.

53 Filings
2020 Period
2020 filings (53)
Filing Released Lang
Oasmia’s partner Elevar Therapeutics signs licensing agreement with Inceptua Group for the commercialization of Apealea® (paclitaxel micellar) in Europe
Regulatory Filings
2020-12-28 English
Oasmias partner Elevar tecknar licensavtal med Inceptua Group för kommersialisering av Apealea® i Europa
M&A Activity
2020-12-28 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report H1 2021
2020-12-09 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report H2 2020
2020-12-09 English
Oasmia’s Partner Elevar Provides an Update on Apealea Development Plans in Ovarian Cancer
M&A Activity
2020-12-03 English
Oasmias partner Elevar ger uppdatering om utvecklingsplanerna för Apealea i äggstockscancer
Regulatory Filings
2020-12-03 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-11-30 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-11-26 English
Valberedning utsedd inför Oasmias årsstämma 2021
Board/Management Information
2020-11-20 Swedish
Nomination Committee appointed for the 2021 Annual General Meeting in Oasmia
Board/Management Information
2020-11-20 English
Oasmia åläggs vite av disciplinnämnden vid Nasdaq Stockholm
Legal Proceedings Report
2020-10-14 Swedish
The Disciplinary Committee of Nasdaq Stockholm orders Oasmia to pay a fine
Legal Proceedings Report
2020-10-14 English
Oasmia’s partner Elevar Therapeutics signs agreement with Taiba Middle East FZ LLC for commercialization of Apealea® in the Middle East and North Africa Region
Regulatory Filings
2020-10-05 English
Oasmias partner Elevar Therapeutics ingår avtal med Taiba Middle East FZ LLC för kommersialisering av Apealea® i Mellanöstern och Nordafrika
Regulatory Filings
2020-10-05 Swedish
Oasmia väcker talan mot bolagets tidigare styrelse
Legal Proceedings Report
2020-09-25 Swedish
Oasmia Brings an Action against the Former Board of Directors
Legal Proceedings Report
2020-09-25 English
Stämmokommuniké från årsstämma i Oasmia Pharmaceutical AB
AGM Information
2020-09-09 Swedish
Report from Annual General Meeting of Oasmia Pharmaceutical AB
AGM Information
2020-09-09 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q2 2020
2020-09-09 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-09-09 English
Oasmia Pharmaceutical utser Fredrik Järrsten till Chief Financial Officer (CFO)
Board/Management Information
2020-09-08 Swedish
Oasmia Pharmaceutical Appoints Fredrik Järrsten as Chief Financial Officer
Board/Management Information
2020-09-08 English
Oasmia’s Nomination Committee revises its proposal for the AGM regarding Board of Directors
Board/Management Information
2020-09-02 English
Oasmias valberedning reviderar sitt förslag till årsstämman avseende val av styrelse
AGM Information
2020-09-02 Swedish
CFO of Oasmia, Michael af Winklerfelt has resigned
Board/Management Information
2020-08-31 English
Oasmias CFO Michael af Winklerfelt har sagt upp sig
Board/Management Information
2020-08-31 Swedish
Annual Report 2020
Annual Report FY 2020
2020-08-19 Swedish
Annual Report 2020
Annual Report FY 2020
2020-08-19 English
Kallelse till årsstämma i Oasmia Pharmaceutical AB
AGM Information
2020-08-10 Swedish
Notice of Annual General Meeting in Oasmia Pharmaceutical AB
AGM Information
2020-08-10 English
Oasmia’s partner Elevar Therapeutics and Tanner Pharma Announce Global Named Patient Program to Provide Access to Apealea®
Regulatory Filings
2020-07-27 English
Oasmias partner Elevar Therapeutics och Tanner Pharma startar ett globalt Named Patient Program för att göra Apealea® tillgängligt för patienter
Legal Proceedings Report
2020-07-27 Swedish
Regulatory Filings 2020
Regulatory Filings
2020-06-18 English
Audit Report / Information 2020
Audit Report / Information FY 2020
2020-06-18 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report FY 2020
2020-06-18 English
Oasmia Pharmaceutical supplements bulletin from Extraordinary General Meeting
AGM Information
2020-05-14 English
Oasmia Pharmaceutical kompletterar kommuniké från extra bolagsstämma
AGM Information
2020-05-14 Swedish
Kommuniké från Oasmia Pharmaceuticals extra bolagsstämma
Declaration of Voting Results & Voting Rights Announcements
2020-05-14 Swedish
Oasmia Pharmaceutical Announces Results of Extraordinary General Meeting and Board Changes
Declaration of Voting Results & Voting Rights Announcements
2020-05-14 English
Oasmia announces outcome of strategic review to deliver long-term, profitable growth as a specialty pharma company
Regulatory Filings
2020-05-13 English
Oasmia presenterar en strategisk översyn för långsiktig, lönsam tillväxt som specialty pharma-bolag
Management Reports
2020-05-13 Swedish
Notice of extraordinary general meeting in Oasmia Pharmaceutical AB
AGM Information
2020-04-17 English
Kallelse till extra bolagsstämma i Oasmia Pharmaceutical AB
AGM Information
2020-04-17 Swedish
Oasmias valberedning föreslår förändringar i styrelsen
Board/Management Information
2020-04-17 Swedish
Oasmia Nomination Committee suggest changes in the Board of Directors
Board/Management Information
2020-04-17 English
Interim / Quarterly Report 2020
Interim / Quarterly Report 9M 2020
2020-03-27 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report 9M 2020
2020-03-27 English
Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea® with an upfront payment of USD 20 million, milestone payments with a potential of up to USD 678 million and
Regulatory Filings
2020-03-25 English
Oasmia och Elevar ingår globalt strategiskt samarbete för kommersialisering av Apealea® med en upfront payment om 20 MUSD, milstolpsbetalningar med potential upp till 678 MUSD samt tvåsiffriga procent
Regulatory Filings
2020-03-25 Swedish
Oasmia appoints new CEO
Board/Management Information
2020-02-14 English
Oasmia utser ny VD
Board/Management Information
2020-02-14 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-01-02 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-01-02 English